BOLOGNA, Italy--(BUSINESS WIRE)-- Silicon Biosystems, S.p.A., a provider of specialized molecular and cell biology technology, today announced that it has formed a U.S. subsidiary operation, Silicon Biosystems, Inc., to be headquartered in San Diego, California. The newly formed business will focus on commercial operations and the development of the North American research and clinical diagnostics markets for the company’s DEPArray™ technology platform.
“The formation of our own commercial operation in the U.S. represents a significant step forward for our business,” stated Giuseppe Giorgini, CEO of Silicon Biosystems, S.p.A. “Our DEPArray™ platform will allow clinicians and researchers working to advance personalized medicine in areas such as clinical oncology to identify new biomarkers and improve patient treatment based on genetic information they have previously not had access to. We are excited to begin commercial discussions with thought leaders in the U.S.”
The company’s DEPArray™ technology exploits microelectronics and the principles of dielectrophoresis to isolate and manipulate cells in a suspension matrix. The approach, patented by Silicon Biosystems, offers the unique possibility of controlling individual cells and micro-particles inside a disposable cartridge. The DEPArray™ platform makes it possible to find, sort, select and separate individual cells for further analysis or culturing.
For more information on Silicon Biosystems, Inc., visit www. siliconbioUSA.com.
About Silicon Biosystems
Silicon Biosystems, S.p.A. is based in Bologna, Italy and has developed a set of proprietary solutions called lab-on-a-chip technologies, targeted at miniaturized cell-biology testing. Silicon Biosystems is one of the most innovative start-ups in the field of "lab-on-a-chip," based on active substrates, as testified by a number of awards and recognitions. The company is also an industrial member of the nano2Life EC Network of Excellence on nanobiotechnologies.
